PKCε Inhibitor Peptide
PKCε Inhibitor Peptide 性质
| 沸点 | 1280.1±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.288±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：10mg/mL； PBS（pH 7.2）：5 mg/mL |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 3.28±0.10(Predicted) |
| 颜色 | 白色至米白色 |
PKCε Inhibitor Peptide 用途与合成方法
|
PKCε
|
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose.
Epsilon-V1-2 (ε-V1-2; 1 µM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes.
Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels.
| Animal Model: | C57BL/6J mice transplanted the hearts of FVB mice |
| Dosage: | 20 mg/kg/day |
| Administration: | 0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks |
| Result: | Significantly improved the beating score throughout the treatment. |
PKCε Inhibitor Peptide 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-08-19 | HY-P0154 | PKCε Inhibitor Peptide | 182683-50-7 | 5mg | 1800 |
| 2024-08-19 | HY-P0154 | PKCε Inhibitor Peptide | 182683-50-7 | 10mg | 3200 |
